We recently compiled a list of the 9 Most Undervalued Healthcare Stocks to Buy Now. Novavax, Inc. tops our list of the most undervalued stocks.
TheFly reported on April 9 that B. Riley Financial increased its price target on NVAX from $16 to $18 while maintaining a Buy rating. The update reflected expectations that ongoing shareholder activism focused on governance and cost structure could lead to changes in board composition and additional improvements to the company’s balance sheet.
Separately, on April 18, Sanofi and Novavax, Inc. (NASDAQ:NVAX) reported results from the COMPARE Phase 4 clinical trial, the first direct head-to-head study assessing tolerability between protein-based Nuvaxovid and an mRNA COVID-19 vaccine, mNEXSPIKE developed by Moderna. The randomized, double-blind study demonstrated that Nuvaxovid produced significantly lower systemic reactogenicity across all key measured outcomes, indicating fewer expected post-vaccination side effects compared with the comparator vaccine.
Findings were presented at a major infectious disease conference in Munich, Germany. The results reinforce the established safety and tolerability profile of Nuvaxovid and are intended to support broader confidence in the vaccine. They also align with ongoing commercialization efforts led by Sanofi for the upcoming vaccination season, with the data potentially contributing to improved public acceptance and uptake of protein-based COVID-19 vaccination options.
Novavax, Inc. is a biotechnology company based in Maryland that develops vaccines for infectious diseases. It uses recombinant protein nanoparticle technology and its Matrix-M adjuvant to enhance immune response.
READ NEXT: Top 10 AI-Powered Biotech Stocks to Buy Right Now and 10 Most Undervalued Dow Stocks to Buy Now.
